CEDAR

Scientific Reference

KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV)

Evidence profile: Component evidence only — this formulation has not itself been studied

The KLOW Protocol is a four-peptide regenerative blend combining GHK-Cu, TB-500 (Thymosin Beta-4), BPC-157, and KPV. It builds upon the GLOW protocol by incorporating KPV, a tripeptide with anti-inflammatory activity, to enhance tolerability and broaden mechanistic coverage. Typical formulations contain approximately 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual peptides have established research backgrounds, no clinical trials have evaluated this specific combination, and all effects remain theoretical based on additive and complementary mechanisms.

Mechanism of Action

The KLOW Protocol integrates four complementary mechanisms: GHK-Cu modulates gene expression and stimulates collagen synthesis; TB-500 enhances cell migration and cytoskeletal repair; BPC-157 upregulates growth factors and promotes angiogenesis; and KPV inhibits NF-κB signaling, reducing inflammation. Together, these pathways aim to create a synergistic regenerative and anti-inflammatory environment, though this combination has not been clinically validated.

Molecular Information

  • Type: Multi-peptide protocol

Published Research

  • RGN-259 neurotrophic keratopathy phase III

    0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    Sosne G et al. · International journal of molecular sciences · 2022 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 36613994 — View on PubMed

  • The effect of thymosin treatment of venous ulcers

    Guarnera G et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536470 — View on PubMed

  • A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

    Ruff D et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536472 — View on PubMed

  • Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

    Miller TR et al. · Archives of facial plastic surgery · 2006 · Clinical · Evidence for GHK-Cu

    PMID 16847171 — View on PubMed

  • A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

    Bishop JB et al. · Journal of vascular surgery · 1992 · Clinical · Evidence for GHK-Cu

    PMID 1495150 — View on PubMed

  • Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK et al. · The American journal of sports medicine · 2026 · Review · Evidence for BPC-157

    PMID 41476424 — View on PubMed